Wells Fargo’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-20,751
Closed -$695K 7569
2026
Q1
$695K Sell
20,751
-31,892
-61% -$1.25M ﹤0.01% 3961
2025
Q4
$2.44M Buy
52,643
+22,163
+73% +$1.22M ﹤0.01% 3280
2025
Q3
$2.06M Buy
30,480
+9,320
+44% +$691K ﹤0.01% 3273
2025
Q2
$1.77M Buy
21,160
+8,687
+70% +$650K ﹤0.01% 3299
2025
Q1
$891K Sell
12,473
-74
-0.6% -$3.6K ﹤0.01% 3718
2024
Q4
$564K Buy
12,547
+3,610
+40% +$187K ﹤0.01% 4091
2024
Q3
$451K Buy
8,937
+1,291
+17% +$61.8K ﹤0.01% 4063
2024
Q2
$312K Buy
7,646
+7,082
+1,256% +$300K ﹤0.01% 4216
2024
Q1
$24.1K Buy
564
+449
+390% +$20.3K ﹤0.01% 5527
2023
Q4
$4.63K Buy
115
+82
+248% +$2.33K ﹤0.01% 5968
2023
Q3
$974 Sell
33
-7
-18% -$42 ﹤0.01% 6211
2023
Q2
$172 Buy
40
+2
+5% +$9 ﹤0.01% 6743
2023
Q1
$81 Hold
38
﹤0.01% 6983
2022
Q4
$75 Buy
38
+1
+3% +$1 ﹤0.01% 6870
2022
Q3
$0 Sell
37
-6
-14% -$15 ﹤0.01% 7286
2022
Q2
$0 Buy
43
+20
+87% +$55 ﹤0.01% 7417
2022
Q1
$0 Hold
23
﹤0.01% 7735
2021
Q4
$0 Hold
23
﹤0.01% 7746
2021
Q3
$0 Sell
23
-1
-4% -$14 ﹤0.01% 7456
2021
Q2
$0 Sell
24
-1,230
-98% -$20.8K ﹤0.01% 7379
2021
Q1
$24K Sell
1,254
-4,408
-78% -$142K ﹤0.01% 6100
2020
Q4
$163K Sell
5,662
-1,331
-19% -$38.4K ﹤0.01% 5166
2020
Q3
$263K Buy
6,993
+3,241
+86% +$94.7K ﹤0.01% 4800
2020
Q2
$125K Buy
3,752
+3,743
+41,589% +$162K ﹤0.01% 5125
2020
Q1
$0 Buy
+9
New +$383 ﹤0.01% 6728

Wells Fargo's SLNO Position: Q2 2026 in Review

Wells Fargo sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 20,751 shares — an estimated $695K sold.

Wells Fargo first reported a position in SLNO in Q1 2020 and held it in 25 quarters. The position peaked at $2.44M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Wells Fargo reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 20,751 Soleno Therapeutics shares in Q2 2026, an estimated $695K.
  • Wells Fargo first reported a position in Soleno Therapeutics in Q1 2020 and held it in 25 quarters.
  • Wells Fargo's Soleno Therapeutics position peaked at $2.44M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.